Free Trial
→ Nvidia CEO Makes First Ever Tesla Announcement (From Brownstone Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$193.27
+0.6%		$180.49
$140.68
▼
$194.40
$465.34B0.49.68 million shs7.73 million shs
Kenvue Inc. stock logo
KVUE
Kenvue
$15.30
+8.4%		$18.54
$14.05
▼
$25.17
$29.34B0.7240.99 million shs51.88 million shs
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$77.50
+2.3%		$62.55
$33.31
▼
$93.25
$4.82B2.21.69 million shs1.24 million shs
Analysts Agree—These Gold Picks Outshine the Rest Cover
Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
+0.77%+1.37%+9.20%+18.10%+17.64%
Kenvue Inc. stock logo
KVUE
Kenvue
+8.91%-8.23%-16.43%-30.45%-29.58%
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
+2.34%-10.92%+30.87%+39.69%+64.93%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$193.27
+0.6%		$180.49
$140.68
▼
$194.40
$465.34B0.49.68 million shs7.73 million shs
Kenvue Inc. stock logo
KVUE
Kenvue
$15.30
+8.4%		$18.54
$14.05
▼
$25.17
$29.34B0.7240.99 million shs51.88 million shs
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$77.50
+2.3%		$62.55
$33.31
▼
$93.25
$4.82B2.21.69 million shs1.24 million shs
Analysts Agree—These Gold Picks Outshine the Rest Cover
Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
+0.77%+1.37%+9.20%+18.10%+17.64%
Kenvue Inc. stock logo
KVUE
Kenvue
+8.91%-8.23%-16.43%-30.45%-29.58%
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
+2.34%-10.92%+30.87%+39.69%+64.93%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.73
Moderate Buy$199.593.27% Upside
Kenvue Inc. stock logo
KVUE
Kenvue
2.38
Hold$21.1838.40% Upside
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
2.83
Moderate Buy$74.00-4.52% Downside

Current Analyst Ratings Breakdown

Latest JNJ, PTGX, and KVUE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/17/2025
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Price TargetBuy$72.00 ➝ $96.00
10/15/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Argus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Price Target$210.00
10/15/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Price TargetOutperform$174.00 ➝ $209.00
10/15/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Set Price Target$190.00
10/15/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Price TargetHold$165.00 ➝ $190.00
10/15/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Price TargetBuy$213.00 ➝ $215.00
10/15/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Price TargetNeutral$198.00 ➝ $204.00
10/14/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated RatingBuy
10/14/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Price TargetBuy$190.00 ➝ $214.00
10/14/2025
Kenvue Inc. stock logo
KVUE
Kenvue
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated RatingHold (C-)
10/13/2025
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated RatingOutperform
(Data available from 10/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$92.15B5.05$13.20 per share14.64$29.69 per share6.51
Kenvue Inc. stock logo
KVUE
Kenvue
$15.46B1.90$1.60 per share9.59$5.04 per share3.04
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$434.43M11.10$4.62 per share16.76$11.33 per share6.84
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$14.07B$10.3618.6517.462.2627.26%33.08%13.30%N/A
Kenvue Inc. stock logo
KVUE
Kenvue
$1.03B$0.7420.6812.342.039.37%20.06%7.78%11/6/2025 (Estimated)
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$275.19M$0.70110.72N/AN/A24.88%8.12%7.41%11/6/2025 (Estimated)

Latest JNJ, PTGX, and KVUE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/6/2025Q3 2025
Kenvue Inc. stock logo
KVUE
Kenvue
$0.27N/AN/AN/A$3.83 billionN/A
11/6/2025Q3 2025
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
-$0.59N/AN/AN/A$5.41 millionN/A
10/14/2025Q3 2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.76$2.80+$0.04$2.12$23.73 billion$23.99 billion
8/7/2025Q2 2025
Kenvue Inc. stock logo
KVUE
Kenvue
$0.28$0.29+$0.01$0.22$3.94 billion$3.84 billion
8/6/2025Q2 2025
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
-$0.53-$0.55-$0.02-$0.55$8.32 million$5.55 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$5.202.69%N/A50.19%64 Years
Kenvue Inc. stock logo
KVUE
Kenvue
$0.835.42%N/A112.16%1 Years
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
N/AN/AN/AN/AN/A

Latest JNJ, PTGX, and KVUE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/14/2025
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
quarterly$1.302.72%11/25/202511/25/202512/9/2025
7/30/2025
Kenvue Inc. stock logo
KVUE
Kenvue
quarterly$0.20753.74%8/13/20258/13/20258/27/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.50
1.01
0.76
Kenvue Inc. stock logo
KVUE
Kenvue
0.66
0.98
0.68
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
N/A
16.97
16.97

Institutional Ownership

CompanyInstitutional Ownership
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
69.55%
Kenvue Inc. stock logo
KVUE
Kenvue
97.64%
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
98.63%

Insider Ownership

CompanyInsider Ownership
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.16%
Kenvue Inc. stock logo
KVUE
Kenvue
1.68%
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
4.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
138,1002.41 billion2.40 billionOptionable
Kenvue Inc. stock logo
KVUE
Kenvue
22,0001.92 billion1.89 billionOptionable
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
12062.21 million59.16 millionOptionable

Recent News About These Companies

Johnson and Johnson logo seen on a smartphone screen with stock trading
Johnson & Johnson's M&A Strategy Is the Real Story for Investors (PTGX)
...
October 18 at 12:04 PM  |  marketbeat.comhttps://www.marketbeat.com/stock-ideas/johnson-and-johnsons-m-and-a-strategy-is-the-real-story-for-investors/
Protagonist Therapeutics price target raised to $96 from $72 at Citi
October 17 at 3:46 PM  |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/protagonist-therapeutics-price-target-raised-to-96-from-72-at-citi/ar-AA1OFhk5
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Average Recommendation of "Moderate Buy" from Brokerages
October 17 at 4:31 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/protagonist-therapeutics-inc-nasdaqptgx-receives-average-recommendation-of-moderate-buy-from-brokerages-2025-10-17/
Protagonist Therapeutics (NASDAQ:PTGX) Shares Gap Down Following Insider Selling
October 17 at 2:17 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30377036
Protagonist Therapeutics (NASDAQ:PTGX) Shares Gap Down After Insider Selling
October 15 at 10:27 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/protagonist-therapeutics-nasdaqptgx-shares-gap-down-after-insider-selling-2025-10-15/
Protagonist Therapeutics (NASDAQ:PTGX) Director William Waddill Sells 12,000 Shares
October 15 at 4:27 AM  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-ptgx-insider-buying-and-selling-2025-10-15/
William Waddill Sells 12,000 Shares of Protagonist Therapeutics (NASDAQ:PTGX) Stock
October 14, 2025  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/william-waddill-sells-12000-shares-of-protagonist-therapeutics-nasdaqptgx-stock-2025-10-14/
Protagonist Therapeutics falls amid a report J&J deal price may be lower
October 13, 2025  |  msn.comhttps://www.msn.com/en-us/money/topstocks/protagonist-therapeutics-falls-amid-a-report-j-j-deal-price-may-be-lower/ar-AA1OnUBH
Protagonist Therapeutics Stock Gains 30% as J&J Reportedly Eyes Deal
October 13, 2025  |  zacks.comhttps://www.zacks.com/stock/news/2767782/protagonist-therapeutics-stock-gains-30-as-j-j-reportedly-eyes-deal?cid=cs-stocknewsapi-ft-analyst_blog|company_news_medical_sector-2767782
Protagonist Therapeutics (NASDAQ:PTGX) Shares Down 4.8% - What's Next?
October 13, 2025  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/protagonist-therapeutics-nasdaqptgx-shares-down-48-whats-next-2025-10-13/
Stocks Showing Market Leadership: Protagonist Therapeutics Earns 96 RS Rating
October 13, 2025  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/stocks-showing-market-leadership-protagonist-therapeutics-earns-96-rs-rating/ar-AA1OnFx7
Protagonist Therapeutics, Inc. $PTGX Stock Position Cut by Inspire Investing LLC
October 13, 2025  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-protagonist-therapeutics-inc-ptgx-stock-position-cut-by-inspire-investing-llc-2025-10-13/
Protagonist Therapeutics (NASDAQ:PTGX) Stock Price Up 9.4% - What's Next?
October 11, 2025  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/protagonist-therapeutics-nasdaqptgx-stock-price-up-94-whats-next-2025-10-10/
Protagonist Therapeutics (NASDAQ:PTGX) Sets New 12-Month High - Here's What Happened
October 11, 2025  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/protagonist-therapeutics-nasdaqptgx-sets-new-12-month-high-heres-what-happened-2025-10-11/
Protagonist Therapeutics' (PTGX) "Buy" Rating Reiterated at HC Wainwright
October 11, 2025  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30368521
Johnson & Johnson in talks to acquire Protagonist Therapeutics, source says
October 10, 2025  |  msn.comhttps://www.msn.com/en-us/money/news/johnson-johnson-in-talks-to-acquire-protagonist-therapeutics-wsj-reports/ar-AA1Oejh0
H.C. Wainwright Keeps Their Buy Rating on Protagonist Therapeutics (PTGX)
October 10, 2025  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/PTGX/pressreleases/35332570/hc-wainwright-keeps-their-buy-rating-on-protagonist-therapeutics-ptgx/
Protagonist Therapeutics stock surges after J&J acquisition talks report
October 10, 2025  |  za.investing.comhttps://za.investing.com/news/stock-market-news/protagonist-therapeutics-stock-surges-after-jj-acquisition-talks-report-3915096
J&J reportedly in talks to buy Protagonist
October 10, 2025  |  msn.comhttps://www.msn.com/en-us/money/companies/j-j-reportedly-in-talks-to-buy-protagonist/ar-AA1Oejc7
Why Did Protagonist Therapeutics Stock Soar Today?
October 10, 2025  |  msn.comhttps://www.msn.com/en-us/money/topstocks/why-did-protagonist-therapeutics-stock-soar-today/ar-AA1OeC6y
Johnson & Johnson in talks to acquire Protagonist Therapeutics, WSJ reports
October 10, 2025  |  reuters.comhttps://www.reuters.com/business/healthcare-pharmaceuticals/johnson-johnson-talks-acquire-protagonist-therapeutics-wsj-reports-2025-10-10/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
SoundHound on cellphone
SoundHound Breaks Critical Resistance: How High Can It Get Now?
By Thomas Hughes | September 28, 2025
A grocery cart with two bottles of pharmaceuticals is heading down a steep down ramp
Trump’s Drug Price Cuts: Boom or Bust for These 3 Pharma Giants
By Gabriel Osorio-Mazilli | October 6, 2025
Big Pharma, health care, pharmaceutical industry and medical business vintage news and newspaper printing. Abstract concept retro headlines 3d illustration. — Photo
Why AbbVie and Johnson & Johnson Could Outperform Pfizer
By Chris Markoch | October 8, 2025
JNJ on cellphone
Johnson & Johnson Stock Can Keep Rising as Strategy Pays Off
By Thomas Hughes | October 15, 2025
Johnson and Johnson logo seen on a smartphone screen with stock trading
Johnson & Johnson's M&A Strategy Is the Real Story for Investors
By Jeffrey Neal Johnson | October 18, 2025
Johnson & Johnson stock logo

Johnson & Johnson NYSE:JNJ

$193.26 +1.15 (+0.60%)
Closing price 10/17/2025 03:59 PM Eastern
Extended Trading
$192.96 -0.30 (-0.16%)
As of 10/17/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Kenvue stock logo

Kenvue NYSE:KVUE

$15.30 +1.19 (+8.45%)
Closing price 10/17/2025 03:59 PM Eastern
Extended Trading
$15.34 +0.04 (+0.25%)
As of 10/17/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair, sun, and other care products under the Neutrogena, Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Rogaine, and OGX brand names. The Essential Health segment offers oral and baby, women's health, wound, and other care products under the Listerine, Johnson's, Band-Aid, and Stayfree, o.b., tampons, Carefree, and Desitin Diaper Rash brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey.

Protagonist Therapeutics stock logo

Protagonist Therapeutics NASDAQ:PTGX

$77.50 +1.77 (+2.34%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$77.50 0.00 (0.00%)
As of 10/17/2025 06:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas